Full history for every metric is available with a Kvantra account
Lannett Company, Inc. (LCI)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 637 | 685 | 655 | 546 | 479 | 341 | 311 |
| Operating profit | $m | -70 | -57 | |||||
| Net profit | $m | -1 | 29 | -272 | -33 | -363 | -232 | -259 |
| EPS reported | $ | -22.96 | -25.30 | |||||
| Operating cashflow per share | $ | -0.71 | -0.71 | |||||
| Capex per share | $ | 1.04 | 1.04 | |||||
| FCF per share | $ | -1.75 | -1.75 | |||||
| Free cash flow | $m | -18 | -65 | |||||
| Net debt | $m | 539 | 582 | |||||
| Book value equity | $m | -251 | -412 | |||||
| Book value per share | $ | -24.89 | -39.98 | |||||
| Number of shares | m | 10.09 | 10.31 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.09 | -0.02 | |||||
| P/S LTM | x | 0.07 | 0.02 | |||||
| P/FCF LTM | x | -1.33 | -0.11 | |||||
| EV/EBITDA LTM | x | -4.78 | -3.68 | |||||
| EV/Sales LTM | x | 1.65 | 1.90 | |||||
| Earnings Yield LTM | % | -989.69% | -3349.5% | |||||
| FCF Yield | % | -75.26% | -874.17% | |||||
| Quality | ||||||||
| ROE | % | 92.26% | 166.31% | |||||
| ROIC | % | -18.22% | -18.22% | |||||
| Operating margin | % | -20.62% | -20.62% | |||||
| Gross margin | % | 9.74% | 9.74% | |||||
| FCF/Sales | % | -5.17% | -5.17% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -28.86% | -16.58% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.03 | -0.10 | |||||
| Net Debt/EBITDA | x | -4.58 | -4.58 | |||||
| EBIT/Net interest | x | -1.21 | -1.21 | |||||
| Net debt/market cap | % | 2303.7% | 7883.6% | |||||
| Net debt/Equity | x | -2.15 | -1.41 | |||||
| Gross debt/equity | x | -2.50 | -1.55 | |||||
Company overview
Lannett Company, Inc. operates as a U.S.-based pharmaceutical firm dedicated to the comprehensive process of developing, manufacturing, packaging, commercializing, and distributing generic versions of established brand-name drugs. Its extensive product portfolio encompasses a wide array of dosage forms, including solid oral, extended-release, topical, liquid, nasal, ophthalmic, injectable, patch, foam, buccal, sublingual, and suspension preparations. These generic medications address a broad spectrum of therapeutic areas, such as cardiovascular health, central nervous system disorders, endocrinology, gastrointestinal issues, infectious diseases, pain management, respiratory conditions, and mental health. Notable among its offerings are generic versions of critical medications such as Levothyroxine Sodium, Fluphenazine, Posaconazole, Verapamil SR, Methylphenidate, Omeprazole, and Sumatriptan Nasal spray, alongside others like Amphetamine IR tablets and cocaine hydrochloride solution. Lannett serves a broad and diverse client base, encompassing generic pharmaceutical distributors, drug wholesalers, major chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, and governmental entities. The company actively engages in strategic partnerships, maintaining supply and development agreements with key collaborators such as Summit Bioscience LLC, HEC Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and numerous other entities. Founded in 1942, Lannett Company, Inc. maintains its headquarters in Trevose, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lannett Company, Inc. (LCI)
Lannett Company, Inc. operates as a U.S.-based pharmaceutical firm dedicated to the comprehensive process of developing, manufacturing, packaging, commercializing, and distributing generic versions of established brand-name drugs. Its extensive product portfolio encompasses a wide array of dosage forms, including solid oral, extended-release, topical, liquid, nasal, ophthalmic, injectable, patch, foam, buccal, sublingual, and suspension preparations. These generic medications address a broad spectrum of therapeutic areas, such as cardiovascular health, central nervous system disorders, endocrinology, gastrointestinal issues, infectious diseases, pain management, respiratory conditions, and mental health. Notable among its offerings are generic versions of critical medications such as Levothyroxine Sodium, Fluphenazine, Posaconazole, Verapamil SR, Methylphenidate, Omeprazole, and Sumatriptan Nasal spray, alongside others like Amphetamine IR tablets and cocaine hydrochloride solution. Lannett serves a broad and diverse client base, encompassing generic pharmaceutical distributors, drug wholesalers, major chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, and governmental entities. The company actively engages in strategic partnerships, maintaining supply and development agreements with key collaborators such as Summit Bioscience LLC, HEC Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and numerous other entities. Founded in 1942, Lannett Company, Inc. maintains its headquarters in Trevose, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free